Abivax Prepares to Report Results While Trading Near Technical Lows and Analyst Targets Diverge

Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.

Part 2.1: Price Behavior Around Earnings

Abivax typically reports earnings after market close, meaning Day 0 reflects anticipatory trading before results are released, while Day +1 captures the market's first full reaction to the actual numbers.

Historical price behavior around earnings shows significant volatility, with the stock averaging a 7.35% absolute move on Day +1 and a 9.19% intraday range. The most dramatic reaction came in June 2025, when ABVX surged 21.89% the day after earnings with an intraday range of 22.66%—likely reflecting a major positive development or beat. More recently, the March 2026 earnings produced a 4.55% decline on Day +1 despite the 33.64% earnings beat, suggesting investors were disappointed by guidance or other forward-looking commentary.

The December 2025 report triggered a 6.08% decline on Day 0 and a 5.88% drop on Day +1, indicating sustained negative sentiment. In contrast, the September 2025 report saw modest positive movement on Day 0 (+2.24%) that reversed to a slight decline by Day +1. The pattern suggests ABVX earnings are high-stakes events with outsized moves in both directions, and that the market's reaction depends heavily on qualitative factors beyond the headline EPS number—likely pipeline updates, cash burn commentary, and development timelines.

Part 2.2: Options Market Expected Move

The options market is pricing a 7.46% expected move for the upcoming earnings, slightly above the 3.91% average Day 0 move but materially below the 7.35% average Day +1 move from recent history. This suggests options traders may be underpricing the potential volatility, particularly given the stock's 21.89% surge following the June 2025 report and the consistent pattern of moves exceeding 5% in either direction.

Part 3: What Analysts Are Saying

Wall Street maintains a bullish stance on Abivax with a consensus rating of 4.75 (Strong Buy territory) and an average price target of $162.15. The analyst community includes 14 Strong Buy ratings and 2 Hold ratings with zero sell recommendations, reflecting broad confidence in the company's development pipeline despite ongoing losses.

Sentiment has improved over the past month, with Strong Buy ratings increasing from 13 to 14. The price target range spans from $140.00 to $187.00, with the mean target implying 54% upside from the current price of $105.04. Citizens Jmp's $187 target represents the most optimistic view, suggesting potential for nearly 78% appreciation if obefazimod development proceeds successfully.

The recent wave of analyst activity underscores growing interest in the story. Goldman Sachs initiated coverage on September 10, just days before the earnings release, while Jefferies upgraded the stock in late June. Truist Securities' July price target increase to $155 and Piper Sandler's maintained coverage signal that the analyst community sees the current valuation as attractive relative to the pipeline's potential, despite the near-term cash burn and lack of revenue.

Part 4: Technical Picture

The Barchart Technical Opinion has deteriorated sharply heading into earnings, shifting from a 64% Buy signal one month ago to a 56% Sell signal currently, with last week showing a 24% Sell reading. This rapid reversal in technical sentiment reflects mounting selling pressure as the stock has broken down below key support levels.

Timeframe Analysis:

• Short-term (100% Sell): Maximum bearish signal indicates severe near-term downward momentum with no technical support
• Medium-term (50% Buy): Neutral-to-positive reading suggests the intermediate trend remains constructive despite recent weakness
• Long-term (100% Sell): Maximum bearish signal reflects deterioration in the longer-term trend structure

Trend Characteristics: The combination of Weak strength and Average direction suggests a choppy, unconvincing downtrend that could reverse quickly on positive news but lacks the conviction of a strong directional move—creating an uncertain technical environment heading into the high-stakes earnings release.

The stock is trading at $105.04, positioned below all major moving averages—the 5-day ($106.90), 10-day ($112.23), 20-day ($113.30), 50-day ($121.91), 100-day ($118.22), and 200-day ($118.98). This universal breakdown below moving average support is technically significant, indicating the stock has lost all near-term momentum and is in a clear downtrend. The 50-day moving average at $121.91 represents the most critical overhead resistance level, now 16% above the current price. With the stock breaking down ahead of earnings and technical indicators uniformly negative in both short and long timeframes, the setup is cautionary—any disappointment in results or guidance could trigger further technical selling, while a strong beat would need to be substantial to reverse the negative momentum and reclaim the moving average structure.